Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Induction chemotherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    733 result(s) found for: Induction chemotherapy. Displaying page 1 of 37.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-001533-28 Sponsor Protocol Number: AAML0531 Start Date*: 2016-05-03
    Sponsor Name:Children's Oncology Group
    Full Title: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
    Medical condition: Acute myeloid leukaemia
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001633-84 Sponsor Protocol Number: CFZ008 Start Date*: 2015-01-22
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphobla...
    Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10025230 Lymphatic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) FR (Completed) AT (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) GR (Completed) PL (Completed) PT (Completed) BG (Completed) NO (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-004856-24 Sponsor Protocol Number: AC220-A-U302 Start Date*: 2016-09-02
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 t...
    Medical condition: FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) HU (Completed) ES (Ongoing) RO (Ongoing) BE (Completed) PT (Completed) BG (Completed) HR (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002919-18 Sponsor Protocol Number: AC220-A-U202 Start Date*: Information not available in EudraCT
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, a...
    Medical condition: Relapsed or Refractory acute myeloid leukemia (AML) in subjects aged ≥1 month to ≤21 years with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutations following failure of fr...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    20.1 10022891 - Investigations 10076230 Fms-like tyrosine kinase 3 positive PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004977-12 Sponsor Protocol Number: MO19872 Start Date*: 2006-06-22
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy.
    Medical condition: Follicular non Hodgkin's Lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) SK (Completed) IT (Completed) GR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001711-85 Sponsor Protocol Number: PTF202 Start Date*: 2022-03-10
    Sponsor Name:PentixaPharm GmbH
    Full Title: A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphom...
    Medical condition: Central nervous system (CNS) lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DK (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005422-30 Sponsor Protocol Number: AIO-KRK-0212 Start Date*: 2014-01-09
    Sponsor Name:AIO Studien gGmbH
    Full Title: Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumum...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001363-12 Sponsor Protocol Number: TRIANGLE Start Date*: 2016-03-24
    Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III
    Full Title: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial
    Medical condition: Generalized mantle cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026805 Mantle cell lymphoma stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026804 Mantle cell lymphoma stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026803 Mantle cell lymphoma stage II PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000624-33 Sponsor Protocol Number: HO156_AMLSG28/18 Start Date*: 2019-08-01
    Sponsor Name:HOVON Foundation
    Full Title: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with ne...
    Medical condition: Previously untreated Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006657-27 Sponsor Protocol Number: CAIRO3 Start Date*: 2007-01-11
    Sponsor Name:Dutch Colorectal Cancer Group
    Full Title: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with capecitabine, oxaliplatin, and bevacizumab as first-line treatment in patients with advance...
    Medical condition: Advanced colorectal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002202-20 Sponsor Protocol Number: 213400 Start Date*: 2020-12-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Dise...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000328-47 Sponsor Protocol Number: CV185-155 Start Date*: 2015-09-15
    Sponsor Name:Bristol-Myers Squibb
    Full Title: A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemothera...
    Medical condition: Lymphoma, Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA BE (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001076-38 Sponsor Protocol Number: GMI-1271-301 Start Date*: 2018-12-21
    Sponsor Name:GlycoMimetics, Inc.
    Full Title: A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) NL (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003540-21 Sponsor Protocol Number: CPKC412E2301 Start Date*: 2018-05-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412...
    Medical condition: newly diagnosed FLT3 non-mutated acute myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) IT (Completed) PT (Completed) FR (Completed) NO (Completed) ES (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002853-13 Sponsor Protocol Number: EWALL-BOLD Start Date*: 2018-03-01
    Sponsor Name:Goethe Universität Frankfurt
    Full Title: Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Bli...
    Medical condition: Patient aged 56 and 74 with CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003632-23 Sponsor Protocol Number: IC2019-02 Start Date*: 2020-06-17
    Sponsor Name:Institut Curie
    Full Title: LOC-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 with a newly diagnosed...
    Medical condition: Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019562-91 Sponsor Protocol Number: GS-EU-131-0247 Start Date*: 2010-12-13
    Sponsor Name:Gilead Sciences International Ltd
    Full Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of...
    Medical condition: Invasive fungal infections (IFI) in subjects with Acute Lymphoblastic Leukemia (ALL) undergoing remission induction chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) ES (Completed) DE (Completed) GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000891-34 Sponsor Protocol Number: ERA2006001 Start Date*: 2006-05-05
    Sponsor Name:Hôpital Ambroise Paré
    Full Title: A randomized, international, open-label, phase II study of peripheral blood progenitor cell (PBPC) mobilization and engraftment with pegfilgrastim or filgrastim for autologous transplantation in su...
    Medical condition: Multiple Myeloma .
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005595-28 Sponsor Protocol Number: AIO-TRK-0214 Start Date*: 2015-09-29
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial.
    Medical condition: Patients with stage II, IIIA and IIIB non-squamous non-small-cell lung cancer with activating EGFR mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10073254 Neoadjuvant therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004577-14 Sponsor Protocol Number: Blina-CELL Start Date*: 2018-12-05
    Sponsor Name:Ústav hematologie a krevní transfuze
    Full Title: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults.
    Medical condition: Newly diagnosed, previously untreated, Ph-negative B-precursor acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:12:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA